NICE blesses Merck's pricey hep C drug; Canadian lawmakers weigh early supply warnings;

@FiercePharma: If J&J's Zytiga can get pre-chemo indication in prostate cancer, patient pop is twice as big, analysts say. Article | Follow @FiercePharma

> The U.K.'s cost-effectiveness agency recommended Merck's ($MRK) hepatitis C pill Victrelis for use on the National Health Service despite its hefty price tag, saying that the drug's benefits to patients make it cost-effective. Article

> Hi-Tech Pharmacal saw 17% sales growth in its generic division for the latest quarter, on strong performance by its copycat version of GlaxoSmithKline's ($GSK) Flonase spray, but Wockhardt has won approval for a rival generic. Story

> Amid unexpected shortages, Canadian lawmakers are weighing new requirements that drugmakers report impending gaps in their drug supplies. Report

> As California's Alameda County prepares for a final vote on a requirement that drugmakers foot the bill for safe disposal of prescription drugs, PhRMA lodged its opposition to the measure. More

> Contract manufacturer Patheon said higher costs and lower revenues cut into its first-quarter results, leading to a loss of $19.4 million. Report

Biotech News

@FierceBiotech: Pfizer hits recruitment rut in virtual clinical trial, seeks CRO to help with European edition of study. More | Follow @FierceBiotech

@JohnCFierce: Great time to sell to AZ. They're getting murdered in the clinic, need to load up on deals. Analysis | Follow @JohnCFierce

@RyanMFierce: FDA asked to treat anti-superbug drugs like rare disease meds. Story | Follow @RyanMFierce

@MarkHFierce: The stem cell juggernaut goes on: An injection during kidney transplant conquered rejection. Impressive. Article via BBC | Follow @MarkHFierce

> Big trouble seen for targeted cancer drugs. Story

> Merck cancer drug digs into HIV's last hiding places. Article

> Teva, OncoGenex amp up Phase III fight against prostate cancer. News

And Finally... High doses of ADHD drugs may actually impede learning, an animal study found. Release